Therapies that block the CSF-1/CSF-1R axis and that, in general, chemokine-targeted therapies (antiCXCL12 or anti-CCL2) not only have the effect of acting directly on tumor growth and propagation but also target the TME formed by immune cells [21]. Here, CSF1 is linked to neoplasm.